Objectives: To assess the health status of heroin users starting and following 3 months of pharmacotherapy for opioid dependence, and to compare outcomes to a range of other chronic medical illnesses treated with maintenance medication.
I
t is increasingly recognized that substance use disorders share many features with other chronic illnesses. 1 In common with conditions such as hypertension, asthma, and diabetes, the treatment of heroin dependence often involves long-term pharmacotherapy. 1, 2 Improving the physical and mental well-being of people with chronic illnesses are important goals of treatment. A central question to understanding the effectiveness of pharmacotherapy for heroin dependence compared with pharmacotherapy for other chronic illnesses, therefore, is whether response to treatment is similar in terms of these goals. To date, the effectiveness of pharmacotherapy for heroin dependence has primarily been measured in terms of the reduction in heroin use, retention rates in treatment, criminal activity, mortality among heroin users, and transmission of HIV. 3, 4 Although these indicators are relevant when evaluating treatments for heroin dependence, the comparison of treatment outcomes with those for other conditions is limited. 5 Data on the impact of pharmacotherapy for heroin dependence on perceived health status are scarce. One study using the Short Form 36 (SF-36) Health Survey 6, 7 found that at the time of entering a methadone maintenance program, heroin users experienced severe emotional and physical problems. 8 Using SF-36 data collected in a National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD), [9] [10] [11] [12] we aimed to extend the findings of Ryan and White 8 and:
1. compare the health status of untreated heroin-dependent participants with an age comparable cohort from the general Australian population, and 2. assess the change in health status from pretreatment to posttreatment for heroin dependence and compare with the change in health status for a range of other chronic medical illnesses treated with maintenance medication.
METHODS Participants

Heroin-dependent Participants
The study uses data that were collected as part of the Australian NEPOD. [9] [10] [11] [12] Six clinical trials included in NEPOD that evaluated maintenance pharmacotherapies for the treatment of heroin dependence (methadone, buprenorphine, LAAM, and naltrexone after detoxification) collected SF-36 data. Details of the trials are being reported separately. [13] [14] [15] [16] [17] [18] All trials included participants who were dependent on heroin (defined by DSM-IV criteria), aged 18 or older, and able and willing to give informed consent. They excluded participants who were pregnant or nursing, or planning to become pregnant, had relevant serious medical conditions, or psychiatric conditions that prevented giving informed consent. Local ethics committees approved each trial. Data collected from participants who later withdrew consent were excluded.
Six hundred thirty-eight participants' data had been provided by the 6 trials. Three trials included current methadone patients in their samples. 13, 16, 17 These data were excluded (n = 202) given the aim of this study was to examine change in health status following pharmacotherapy. Fortyone heroin users randomized to receive the pharmacotherapy LAAM in one trial were excluded as this treatment is not available in Australia outside of a clinical trial setting. 17 The 69 participants who did not commence treatment after randomization were also excluded, leaving a total of 326 participants' data to analyze, of whom 64% received maintenance treatment with naltrexone, 22% methadone, and 14% buprenorphine.
Outcome Measure
Health Status Health status was measured using the SF-36 health survey. 6, 7 This questionnaire measures 8 dimensions of health and wellbeing: physical functioning, role limitations owing to emotional problems, role limitations owing to physical problems, social functioning, mental health, bodily pain, vitality, and general health perceptions. For each dimension, scores are coded, summed and transformed to a scale from 0 to 100, with higher scores indicating better health. On the basis of these separate subscales, 2 summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) can be calculated using norm-based methods to provide a global measure of physical and mental functioning. 19 These scores have a mean of 50 and a standard deviation of 10. Thus, MCS and PCS scores above (or below) 50 are above (or below) the average in the general population.
The SF-36 is a well studied and widely used self-report measure of health status with demonstrated reliability and construct validity, 7, 19 including for use in Australia. 20 The 
Procedure
Participants completed the SF-36 as part of a detailed intake interview conducted before treatment and at 3-month follow-up. SF-36 subscale and summary scores were calculated using published algorithms. 7, 19 Imputation for missing values was performed, as recommended, when at least 50% of the items for a subscale were completed. The Australian SF-36 normative data 21 were used in the comparison between the general population and trial entrants. As the majority of participants were aged 25 to 34 years, the normative data for that age bracket were used. The MCS and PCS scores for trial participants were calculated using means, standard deviations, and factor score coefficients obtained from the Australian National Health Survey so they could be directly compared with the Australian normative data. 21 In comparisons of the changes in MCS and PCS scores after treatment for heroin dependence with those for other chronic disorders, scores were calculated using means, standard deviations, and factor score coefficients obtained from the US general population as recommended. 19 
Selection of Comparison Disorders
The disorders selected for comparison to heroin dependence were schizophrenia, depression, and diabetes. These conditions were chosen as they are well researched, effectively treated with maintenance medication, often chronic in nature, and likely to have SF-36 data available. The following guidelines were used to select comparison studies: (1) use of the SF-36 and both the MCS and PCS mean scores pretreatment and posttreatment reported (or all 8 subscale means pretreatment and posttreatment to calculate MCS and PCS); (2) evaluation of a specific and conventional maintenance medication; (3) follow-up time frame as close as possible to 3 months; (4) relatively large overall sample size (preferably more than 100); (5) relative recency of data; and (6) medically confirmed diagnoses. Given the objective of the study, criterion 1 and 2 were considered the most important. Although a number of longitudinal outcome studies were found using the SF-36, only 5 studies were found that met these plus the majority of the remaining criteria. References for each study are provided in Table 3 .
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Analyses
For comparison of means, t tests were used. Statistical analyses were performed using SPSS for Windows, Version 11 (SPSS Institute, 1999). Statistical significance was set at P<0.05.
RESULTS
A total of 326 heroin-dependent, treatment-seeking participants who began maintenance treatment with naltrexone, methadone, or buprenorphine were included in the study. The mean age of the sample was 29.6 years (SD = 7.4; range 18 to 56), and 63% were men. The mean age of first heroin use was 20.7 years (SD = 4.9; range 10 to 43). All but 1 participant (an illicit methadone user) had used heroin in the month preceding treatment, the majority (72%) using daily. The mean number of heroin-free days in the month (28 days) before treatment was 4 (SD = 7.9; range 0 to 28). Fifty-one percent of the sample were unemployed, and 18% were employed either part-time or full-time. The remainder were students (5%), engaged in home duties (5%) or received a pension (17%).
A comparison of the SF-36 subscale and summary scores of the 326 heroindependent participants before treatment and the Australian population norms for persons aged 25 to 34 years is shown in extremely poor mental health before commencing pharmacotherapy. Their scores on every SF-36 subscale were significantly worse than the Australian norms, the largest differences observed on the social functioning, role limits physical and mental health subscales (worse by 1.2 SD units or more). The average PCS score of 44.8 before commencing treatment was 0.8 SD units below the population mean, and the MCS score of 32.6, approximately 1.2 SD units below the mean.
At 3 months, a total of 134 participants (41%) were receiving the maintenance pharmacotherapy to which they were originally assigned. Seventeen of these participants either could not be assessed at follow-up (n = 14) or were missing one or more of the 8 SF-36 subscales scores required to calculate PCS and MCS (n = 3), thus the data presented relate to the remaining 117 participants who had data available.
Of these 117 participants, 47% were receiving naltrexone maintenance treatment, 34% methadone, and 19% buprenorphine. A significantly greater proportion of the participants who began treatment with naltrexone discontinued treatment (153/210) compared with methadone (19/70) and buprenorphine (20/46) (w 2 = 50.6, df = 2, P<0.001). There was no difference between the 3 treatment types of naltrexone, methadone, and buprenorphine in the MCS score before pharmacotherapy (33, 34, and 31 respectively, F = 0.381, df = 2, P = 0.681) or at 3-month follow-up (43, 39, and 42, respectively, F = 0.908, df = 2, P = 0.406).
There was a significant difference between the naltrexone, methadone, and buprenorphine treatment groups in the PCS score pretreatment (43, 48, and 45, respectively, F = 3.72, df = 2, P<0.05), with the naltrexone group recording a significantly lower PCS score than the methadone group *Unstandardized mean scores for persons aged 25 to 34 years. n = 4138 is the minimum number of respondents contributing to any one particular score.
wSDs for each subscale and summary score were calculated as follows: SD = the square root of the number of respondents multiplied by the standard error as provided by the Australian Bureau of Statistics.
zMean score for heroin-dependent trial entrants minus mean score for Australian normative population divided by the SD of the normative population. 27 A negative figure indicates heroin-dependent mean worse than population mean.
}Nine cases missing values, being the maximum amount of missing data for any one subscale. 8Twelve cases missing one or more of the 8 SF-36 subscales scores required to calculate the PCS and MCS scores. **P<0.001.
(43 vs. 48, t = 2.72, df = 112, P<0.01). This difference may be related to the fact that a number of the participants starting naltrexone treatment had recently detoxified from heroin and may have been experiencing residual withdrawal symptoms impacting on those subscales contributing most to the PCS score (eg, bodily pain). There was no difference between the naltrexone, methadone, and buprenorphine groups in the PCS score at follow-up (54, 52, and 53, respectively, F = 0.654, df = 2, P = 0.552). Given the singular significant difference at baseline, outcomes for the sample are presented combined across the 3 pharmacotherapies. As shown in Table 2 , the 117 participants retained in pharmacotherapy showed significant improvement across all of the domains of functioning measured by the SF-36, with effect sizes that would be considered medium to large. 20 The PCS score increased significantly to be comparable with the Australian population norm of 53. 19 Scores on the MCS also improved significantly, although they remained substantially below the population average of 50. Along with significant improvement in all SF-36 scores, a comparison between pretreatment and 3-month data showed a significant increase in the number of heroin-free days, increasing from 5 to 25 in the past month (t = 22.51, df = 115, P<0.01).
Comparisons of the changes in PCS and MCS scores after treatment for heroin dependence with those of other chronic disorders are shown in Table 3 . [22] [23] [24] [25] [26] The change observed in both the MCS and PCS (D = 8.3) scores among the heroin-dependent participants after 3 months of pharmacotherapy would be considered large, with an effect size of 0.83. 20 For the PCS score, wThis randomized study included another arm involving treatment with haloperidol, which had poorer PCS and MCS outcomes than olanzapine. zSF-36 subscale scores not reported, only change in PCS and MCS provided. }This randomized study included 2 other arms involving treatment with hypericum extract and placebo. 8This randomized study included 3 arms involving treatment with nortriptyline, interpersonal psychotherapy, or the ''usual care of their primary physicians.'' Results for nortriptyline and interpersonal therapy were combined into a single ''protocol treatment'' group because the outcome analysis was essentially the same when nortriptyline, interpersonal therapy, and usual care were included as distinct groups.
zThis study reported all SF-36 subscale mean scores pretreatment and posttreatment but not PCS and MCS. PCS and MCS scores were calculated using published algorithms.
an extremely large effect size equal to or greater than 1.5.
DISCUSSION
There has been a therapeutic nihilism among the medical profession, policy makers and politicians regarding the management of heroin dependence, 28 compared with the management of other chronic disorders. This paper shows good relative health gains for the management of heroin dependence with pharmacotherapy. Heroin users entering pharmacotherapy are in very poor physical and psychological health compared with the general population. However, for participants who remain in treatment, clinically and statistically significant improvements in physical, emotional, and social well-being occur in just 3 months. Importantly, the health status of treated heroin users improves to a comparable, or greater, degree than that observed with other chronic disorders treated with conventional medication. This finding is important as it suggests that the investment in pharmacotherapies for the heroin-dependent population is at least as beneficial to patients' health status as pharmacotherapies accepted for other chronic conditions. It is now widely acknowledged that the personal burden of illness cannot be described fully by measures of disease status alone 5, 29 ; self-reported information such as difficulty fulfilling personal and family responsibilities, pain, depressed mood, and functional impairment obtained from generic measures such as the SF-36 must also be considered. In this regard, untreated heroin users score significantly worse than the Australian general population, perceiving themselves to be as disabled and distressed as patients with most chronic medical diseases. 19 Their perceived physical health before treatment (PCS = 44.8) was identical to persons experiencing 2 or more serious medical conditions (eg, heart disease, stroke, diabetes). 19 Their perceived mental health (MCS = 32.6) was less than persons experiencing all illnesses surveyed, 19 including cancer, heart disease, stroke and diabetes, and virtually identical to clinically depressed patients (MCS = 32.6 and 33.9, respectively), a profile noted previously. 8 These results demonstrate the dual impact of heroin dependence on both physical and psychological health, but also suggest that the burden of this condition is concentrated in the mental dimension of health, signifying substantial social and role disability owing to emotional problems, frequent psychological distress (feelings of depression and nervousness) and health in general rated 'poor.' As far as we are aware, the SF-36 had not previously been used to report change in health status after pharmacotherapy for heroin dependence, nor to compare treatment outcomes to those achieved with pharmacotherapies for other medical conditions. The 117 participants retained in treatment improved significantly across all the domains of physical and mental health measured. Research experience with the SF-36 suggests that 5 to 10 point changes are clinically meaningful in primary care and chronic disease populations. 7 Therefore, these changes are also clinically significant, as they were all greater than 10 points. Previous research has demonstrated an early (ie, in the first month) and substantial improvement in health-related quality of life of patients in methadone maintenance treatment using the Nottingham Health Profile. 30 Similarly, improved quality of life among opioid-dependent patients treated with methadone or sublingual buprenorphine has been reported using the Lancashire Quality of Life Profile, with no significant differences between the 2 pharmacotherapies. 31 In our study, after just 3 months of continuous treatment with naltrexone, methadone, or buprenorphine, participants' physical health improved to be similar to the general population (from 45.3 to 53. Medical Outcomes Study norms, 19 this improvement represents a greater than one-third decrease in the predicted probability of death within 5 years (from approximately 4.9% to 2.9%). Participants' perception of their mental health while maintained on naltrexone, methadone, or buprenorphine also improved significantly (from 32.9 to 41.4), although scores remained well below the population average of 50. The degree of mental health disruption found in this study highlights the importance of effective methods for screening and dealing with other comorbid psychiatric conditions in the treatment process.
The similarity between substance dependence and other chronic disorders, such as asthma, hypertension, and diabetes in heritability, course, and particularly response to treatment has been highlighted in 2 major reviews. 1, 2 In comparing the changes in health status in response to treatment among heroin users to other patient groups with chronic illness, we found improvements were generally comparable, or larger. The perceived improvement in physical health among treated heroin users was greater than that observed among treated schizophrenic, depressed, and diabetic patients. Improvements in mental health were also greater among treated heroin users than diabetic patients, and comparable with those observed among schizophrenic patients. The only patient group to record greater improvement in mental health were depressed patients treated with imipramine 22 or nortriptyline. 23 Somewhat surprisingly, the MCS score for heroin-dependent participants before treatment was comparable to schizophrenic patients, 24, 25 although their physical component score was generally worse. This is relevant because schizophrenia has traditionally been considered the most debilitating psychiatric illness, and our results suggest the health-related quality of life of untreated heroin-dependent persons is as poor as that of schizophrenic patients. This raises the issue of the validity of the SF-36 among untreated heroin-dependent samples, upon which there is little published. Many of the features of opioid withdrawal, which are temporary but can be experienced as quite severe, may result in poor ratings on a number of the SF-36 subscales at treatment entry (eg, bodily pain, vitality, mental health). It is open to question whether these ratings reflect the same level of dysfunction as experienced by persons suffering from schizophrenia and other psychiatric disorders, where the burden is quite persistent. A related concern is that the magnitude of the change in SF-36 summary scores is determined in part by baseline values before intervention. From a baseline just below the norm (50) it is hard to achieve a large effect size from treatment. The heroin users in this study had both low physical and mental summary scores and hence more potential for a substantial increase. The comparisons of mean scores with patients with other chronic conditions should be interpreted noting these considerations. There are other qualifications to interpreting the results of this study. First, as this study did not restrict the treatment of concomitant conditions, such as depression or anxiety, it is possible some of the improvements in SF-36 scores were due to such treatment. Second, only the follow-up results for participants remaining in treatment are presented. However, additional analyses show significantly higher PCS and MCS scores for the 117 participants retained in treatment compared with 84 of the 192 who dropped out during the first 3 months and could be assessed at 3 months (PCS = 52 vs. 48 respectively, t test = 3.49, P<0.05; MCS = 43 vs. 36 respectively, t test = 3.47, P<0.05). In addition, when the subset of 84 participants who dropped out of treatment was compared with the remaining 108 drop-outs there were no statistically significant differences in baseline PCS (44 vs. 42, t test = 1.59, P = NS) and MCS (36 vs. 33, t test = 1.44, P = NS) scores. There were also no differences between participants who remained in treatment and those who did not in age, sex, heroin use, years of heroin use, number of previous treatment attempts (detoxification and methadone maintenance) and SF-36 scores before treatment. This study does not examine differences between pharmacotherapy type and the authors are not suggesting that pharmacotherapy type is irrelevant. The purpose of this paper is to show that treatment with pharmacotherapy for heroin dependence results in significant improvement, comparable to improvements seen with other chronic conditions.
Our findings portray heroin dependence as a condition that markedly compromises psychological and physical health, and support the efficacy of the available pharmacotherapies in lessening this distress and disability. Outcomes research seeks to inform decision-makers about health benefits in terms of changes in what people are able to do and how they feel. 19 The benefit of pharmacotherapy for heroin dependence in terms of these goals seems to be of similar or greater magnitude to that achieved with other chronic disorders treated with a pharmacotherapy. It is hoped that these findings will allow a better understanding of heroin dependence as a serious chronic illness where health care expenditures provide significant health benefits. Further research is required investigating the validity of the SF-36 among heroin-dependent samples and health status outcomes with nonpharmacologic treatment for heroin dependence.
